Clinicopathologic and Prognostic Value of Serum Carbohydrate Antigen 19-9 in Gastric Cancer: A Meta-Analysis.

Abstract

BACKGROUND:

The clinical value of carbohydrate antigen (CA) 19-9 in gastric cancer is controversial. We evaluated the clinicopathologic and prognostic value of CA 19-9 in gastric cancer.

METHODS:

A literature search was conducted in PubMed and Embase databases. Odds ratios (ORs), risk ratios (RR), hazard ratios (HRs), and 95% confidence intervals (CIs) were used as effect measures.

RESULTS:

Thirty-eight studies were included. Results showed that there were significant differences in the incidence of high CA 19-9 levels between stages III/IV and I/II groups (OR = 3.36; 95% CI = 2.34-4.84), the pT3/T4 and pT1/T2 groups (OR = 2.40; 95% CI = 1.60-3.59), the lymph node-positive and node-negative groups (OR = 2.91; 95% CI = 2.21-3.84), the metastasis-positive and metastasis-negative groups (OR = 2.76; 95% CI = 1.12-6.82), and vessel invasion-positive and invasion-negative groups (OR = 1.66; 95% CI = 1.11-2.48). Moreover, CA 19-9 was significantly associated with poor overall survival (HR = 1.83; 95% CI = 1.56-2.15), disease-free survival (HR = 1.85; 95% CI = 1.16-2.95), and disease-specific survival (HR = 1.33; 95% CI = 1.10-1.60) in gastric cancer.

CONCLUSIONS:

Our meta-analysis showed that CA 19-9 indicates clinicopathologic characteristics of gastric cancer and is associated with a poor prognosis.

• Authors: Yong-xi Song, Xuan-zhang Huang, Peng Gao, Jing-xu Sun, Xiao-wan Chen, Yu-chong Yang, Cong Zhang, Hong-peng Liu, Hong-chi Wang, Zhen-ning Wang
• Journal: Disease markers (Dis Markers) Vol. 2015 Pg. 549843 ( 2015) ISSN: 1875-8630 [Electronic] United States
• PMID: 26576068 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review)

Chemical References

• CA-19-9 Antigen

Topics

• CA-19-9 Antigen (blood)
• Case-Control Studies
• Humans
• Neoplasm Metastasis
• Stomach Neoplasms (blood, pathology)